Variations of mitochondrial DNA polymerase γ in patients with Parkinson’s disease
Parkinson’s disease is associated with mitochondrial dysfunction. The POLG1 gene encodes DNA-polymerase γ, which is responsible for the replication of mitochondrial DNA. Mutations in POLG1 cause neurodegenerative diseases such as progressive external ophthalmoplegia and Alpers syndrome. In this stud...
Gespeichert in:
Veröffentlicht in: | Journal of neurology 2013-12, Vol.260 (12), p.3144-3149 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3149 |
---|---|
container_issue | 12 |
container_start_page | 3144 |
container_title | Journal of neurology |
container_volume | 260 |
creator | Ylönen, S. Ylikotila, P. Siitonen, A. Finnilä, S. Autere, J. Majamaa, K. |
description | Parkinson’s disease is associated with mitochondrial dysfunction. The
POLG1
gene encodes DNA-polymerase γ, which is responsible for the replication of mitochondrial DNA. Mutations in
POLG1
cause neurodegenerative diseases such as progressive external ophthalmoplegia and Alpers syndrome. In this study, we investigated if mutations in
POLG1
had any correlation with Parkinson’s disease. Subjects consisted of Finnish patients with early-onset Parkinson’s disease (EOPD,
N
= 441) or late-onset Parkinson’s disease (LOPD,
N
= 263). The
POLG1
gene was screened for nine previously known mutations. Two patients were compound heterozygotes with respect to putatively pathogenic alleles. Twenty-eight patients harbored a heterozygous missense mutation, but the allele frequencies did not differ from those of the controls. Interestingly, the frequency of affected siblings was 4.6-fold higher (95 % confidence interval; 1.09, 19.5) among the patients with EOPD and with heterozygous
POLG1
mutations than among patients without mutations. Clinically the patients with or without
POLG1
mutations did not differ from each other. Our findings provide two lines of evidence suggesting a role for
POLG1
mutations in Parkinson’s disease: (1) identification of patients with compound heterozygous mutations in
POLG1
, and (2) higher frequency of affected siblings among the EOPD patients with heterozygous
POLG1
mutations than among EOPD patients without mutations. |
doi_str_mv | 10.1007/s00415-013-7132-7 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492632473</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490771920</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-81c7b5a0fadc9d3387ab133f079ba11f870e1911e421716c7e3343537b5d8dbe3</originalsourceid><addsrcrecordid>eNqNkDtOxDAQhi0EguVxABrkkiYwYzvrpES8JQQUC63lJA4YEnuxs0J0XINzcA8OwUnwaoESUc1o5vv_4iNkG2EPAeR-BBCYZ4A8k8hZJpfICEVaUOTlMhkBF5DlPBdrZD3GBwAo0mOVrDGBjMGYjcjkVgerB-tdpL6lvR18fe9dk44dPbo8oFPfvfQm6Gjoxzu1jk4TbdwQ6bMd7um1Do_WRe8-X98ibWw0idwkK63uotn6nhvk5uR4cniWXVydnh8eXGQ1l3LICqxllWtodVOXDeeF1BVy3oIsK43YFhIMlohGMJQ4rqXhXPCcp1BTNJXhG2R30TsN_mlm4qB6G2vTddoZP4sKRcnGnAnJ_4OClFgySCgu0Dr4GINp1TTYXocXhaDm3tXCu0re1dy7kimz810_q3rT_CZ-RCeALYCYXu7OBPXgZ8ElO3-0fgE_8o5i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490771920</pqid></control><display><type>article</type><title>Variations of mitochondrial DNA polymerase γ in patients with Parkinson’s disease</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Ylönen, S. ; Ylikotila, P. ; Siitonen, A. ; Finnilä, S. ; Autere, J. ; Majamaa, K.</creator><creatorcontrib>Ylönen, S. ; Ylikotila, P. ; Siitonen, A. ; Finnilä, S. ; Autere, J. ; Majamaa, K.</creatorcontrib><description>Parkinson’s disease is associated with mitochondrial dysfunction. The
POLG1
gene encodes DNA-polymerase γ, which is responsible for the replication of mitochondrial DNA. Mutations in
POLG1
cause neurodegenerative diseases such as progressive external ophthalmoplegia and Alpers syndrome. In this study, we investigated if mutations in
POLG1
had any correlation with Parkinson’s disease. Subjects consisted of Finnish patients with early-onset Parkinson’s disease (EOPD,
N
= 441) or late-onset Parkinson’s disease (LOPD,
N
= 263). The
POLG1
gene was screened for nine previously known mutations. Two patients were compound heterozygotes with respect to putatively pathogenic alleles. Twenty-eight patients harbored a heterozygous missense mutation, but the allele frequencies did not differ from those of the controls. Interestingly, the frequency of affected siblings was 4.6-fold higher (95 % confidence interval; 1.09, 19.5) among the patients with EOPD and with heterozygous
POLG1
mutations than among patients without mutations. Clinically the patients with or without
POLG1
mutations did not differ from each other. Our findings provide two lines of evidence suggesting a role for
POLG1
mutations in Parkinson’s disease: (1) identification of patients with compound heterozygous mutations in
POLG1
, and (2) higher frequency of affected siblings among the EOPD patients with heterozygous
POLG1
mutations than among EOPD patients without mutations.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-013-7132-7</identifier><identifier>PMID: 24122062</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Age ; Aged ; DNA Polymerase gamma ; DNA-Directed DNA Polymerase - genetics ; Female ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Neurology ; Neuroradiology ; Neurosciences ; Original Communication ; Parkinson Disease - enzymology ; Parkinson Disease - genetics ; Pedigree ; Polymorphism, Restriction Fragment Length</subject><ispartof>Journal of neurology, 2013-12, Vol.260 (12), p.3144-3149</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-81c7b5a0fadc9d3387ab133f079ba11f870e1911e421716c7e3343537b5d8dbe3</citedby><cites>FETCH-LOGICAL-c377t-81c7b5a0fadc9d3387ab133f079ba11f870e1911e421716c7e3343537b5d8dbe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00415-013-7132-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00415-013-7132-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24122062$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ylönen, S.</creatorcontrib><creatorcontrib>Ylikotila, P.</creatorcontrib><creatorcontrib>Siitonen, A.</creatorcontrib><creatorcontrib>Finnilä, S.</creatorcontrib><creatorcontrib>Autere, J.</creatorcontrib><creatorcontrib>Majamaa, K.</creatorcontrib><title>Variations of mitochondrial DNA polymerase γ in patients with Parkinson’s disease</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>Parkinson’s disease is associated with mitochondrial dysfunction. The
POLG1
gene encodes DNA-polymerase γ, which is responsible for the replication of mitochondrial DNA. Mutations in
POLG1
cause neurodegenerative diseases such as progressive external ophthalmoplegia and Alpers syndrome. In this study, we investigated if mutations in
POLG1
had any correlation with Parkinson’s disease. Subjects consisted of Finnish patients with early-onset Parkinson’s disease (EOPD,
N
= 441) or late-onset Parkinson’s disease (LOPD,
N
= 263). The
POLG1
gene was screened for nine previously known mutations. Two patients were compound heterozygotes with respect to putatively pathogenic alleles. Twenty-eight patients harbored a heterozygous missense mutation, but the allele frequencies did not differ from those of the controls. Interestingly, the frequency of affected siblings was 4.6-fold higher (95 % confidence interval; 1.09, 19.5) among the patients with EOPD and with heterozygous
POLG1
mutations than among patients without mutations. Clinically the patients with or without
POLG1
mutations did not differ from each other. Our findings provide two lines of evidence suggesting a role for
POLG1
mutations in Parkinson’s disease: (1) identification of patients with compound heterozygous mutations in
POLG1
, and (2) higher frequency of affected siblings among the EOPD patients with heterozygous
POLG1
mutations than among EOPD patients without mutations.</description><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>DNA Polymerase gamma</subject><subject>DNA-Directed DNA Polymerase - genetics</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Original Communication</subject><subject>Parkinson Disease - enzymology</subject><subject>Parkinson Disease - genetics</subject><subject>Pedigree</subject><subject>Polymorphism, Restriction Fragment Length</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkDtOxDAQhi0EguVxABrkkiYwYzvrpES8JQQUC63lJA4YEnuxs0J0XINzcA8OwUnwaoESUc1o5vv_4iNkG2EPAeR-BBCYZ4A8k8hZJpfICEVaUOTlMhkBF5DlPBdrZD3GBwAo0mOVrDGBjMGYjcjkVgerB-tdpL6lvR18fe9dk44dPbo8oFPfvfQm6Gjoxzu1jk4TbdwQ6bMd7um1Do_WRe8-X98ibWw0idwkK63uotn6nhvk5uR4cniWXVydnh8eXGQ1l3LICqxllWtodVOXDeeF1BVy3oIsK43YFhIMlohGMJQ4rqXhXPCcp1BTNJXhG2R30TsN_mlm4qB6G2vTddoZP4sKRcnGnAnJ_4OClFgySCgu0Dr4GINp1TTYXocXhaDm3tXCu0re1dy7kimz810_q3rT_CZ-RCeALYCYXu7OBPXgZ8ElO3-0fgE_8o5i</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Ylönen, S.</creator><creator>Ylikotila, P.</creator><creator>Siitonen, A.</creator><creator>Finnilä, S.</creator><creator>Autere, J.</creator><creator>Majamaa, K.</creator><general>Springer Berlin Heidelberg</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20131201</creationdate><title>Variations of mitochondrial DNA polymerase γ in patients with Parkinson’s disease</title><author>Ylönen, S. ; Ylikotila, P. ; Siitonen, A. ; Finnilä, S. ; Autere, J. ; Majamaa, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-81c7b5a0fadc9d3387ab133f079ba11f870e1911e421716c7e3343537b5d8dbe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>DNA Polymerase gamma</topic><topic>DNA-Directed DNA Polymerase - genetics</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Original Communication</topic><topic>Parkinson Disease - enzymology</topic><topic>Parkinson Disease - genetics</topic><topic>Pedigree</topic><topic>Polymorphism, Restriction Fragment Length</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ylönen, S.</creatorcontrib><creatorcontrib>Ylikotila, P.</creatorcontrib><creatorcontrib>Siitonen, A.</creatorcontrib><creatorcontrib>Finnilä, S.</creatorcontrib><creatorcontrib>Autere, J.</creatorcontrib><creatorcontrib>Majamaa, K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ylönen, S.</au><au>Ylikotila, P.</au><au>Siitonen, A.</au><au>Finnilä, S.</au><au>Autere, J.</au><au>Majamaa, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Variations of mitochondrial DNA polymerase γ in patients with Parkinson’s disease</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>260</volume><issue>12</issue><spage>3144</spage><epage>3149</epage><pages>3144-3149</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><abstract>Parkinson’s disease is associated with mitochondrial dysfunction. The
POLG1
gene encodes DNA-polymerase γ, which is responsible for the replication of mitochondrial DNA. Mutations in
POLG1
cause neurodegenerative diseases such as progressive external ophthalmoplegia and Alpers syndrome. In this study, we investigated if mutations in
POLG1
had any correlation with Parkinson’s disease. Subjects consisted of Finnish patients with early-onset Parkinson’s disease (EOPD,
N
= 441) or late-onset Parkinson’s disease (LOPD,
N
= 263). The
POLG1
gene was screened for nine previously known mutations. Two patients were compound heterozygotes with respect to putatively pathogenic alleles. Twenty-eight patients harbored a heterozygous missense mutation, but the allele frequencies did not differ from those of the controls. Interestingly, the frequency of affected siblings was 4.6-fold higher (95 % confidence interval; 1.09, 19.5) among the patients with EOPD and with heterozygous
POLG1
mutations than among patients without mutations. Clinically the patients with or without
POLG1
mutations did not differ from each other. Our findings provide two lines of evidence suggesting a role for
POLG1
mutations in Parkinson’s disease: (1) identification of patients with compound heterozygous mutations in
POLG1
, and (2) higher frequency of affected siblings among the EOPD patients with heterozygous
POLG1
mutations than among EOPD patients without mutations.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>24122062</pmid><doi>10.1007/s00415-013-7132-7</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-5354 |
ispartof | Journal of neurology, 2013-12, Vol.260 (12), p.3144-3149 |
issn | 0340-5354 1432-1459 |
language | eng |
recordid | cdi_proquest_miscellaneous_1492632473 |
source | MEDLINE; SpringerNature Journals |
subjects | Adult Age Aged DNA Polymerase gamma DNA-Directed DNA Polymerase - genetics Female Humans Male Medicine Medicine & Public Health Middle Aged Mutation Neurology Neuroradiology Neurosciences Original Communication Parkinson Disease - enzymology Parkinson Disease - genetics Pedigree Polymorphism, Restriction Fragment Length |
title | Variations of mitochondrial DNA polymerase γ in patients with Parkinson’s disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A51%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Variations%20of%20mitochondrial%20DNA%20polymerase%20%CE%B3%20in%20patients%20with%20Parkinson%E2%80%99s%20disease&rft.jtitle=Journal%20of%20neurology&rft.au=Yl%C3%B6nen,%20S.&rft.date=2013-12-01&rft.volume=260&rft.issue=12&rft.spage=3144&rft.epage=3149&rft.pages=3144-3149&rft.issn=0340-5354&rft.eissn=1432-1459&rft_id=info:doi/10.1007/s00415-013-7132-7&rft_dat=%3Cproquest_cross%3E1490771920%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490771920&rft_id=info:pmid/24122062&rfr_iscdi=true |